Women at the Crossroads in Gene Editing

1:00 PM - 2:00 PM (EDT), Thursday, June 8, 2023 ・ Session Room 206AB
In 2020, more than 71% of those with PhDs in health and medical sciences were women, strategically positioning female leaders in science to ride the wave of the gene editing revolution. The first CRISPR-based therapeutics and cell-line technology are ushering in the first generation of commercial gene-editing treatments, functionally curing patients with chronic complex diseases like sickle cell and potentially type 1 diabetes. Behind the movement sparked by female Nobel Laureates, it is the female scientists and executives who are leading the charge in the commercial development, regulation and pricing for therapies to revolutionize the way we treat diseases.
Managing Director
Syneos Health
Chief Regulatory Officer
Tessera Therapuetics
Chief Scientific Officer, Pioneering Medicines
Flagship Pioneering
Vice President of in vivo
CRISPR Therapeutics